JournalScan
| The first 150 words of the full text of this article appear below. |
GENERAL CARDIOLOGY
Standard treatment of acute pulmonary embolism (PE) consists of regimens involving anticoagulation therapy alone. Thrombolytic therapy (TT) may provide a mechanism for more rapid thrombus dissolution and improvement in pulmonary blood flow and may therefore offer benefit to certain patient groups, such as those presenting with features of cardiopulmonary compromise. However, previous studies have failed to demonstrate a clear mortality advantage for TT among patients presenting with acute PE, and data for the indications and benefit of TT in this setting are inconsistent. It remains unclear how these mixed reports have influenced the prevalence of TT in both academic and community hospital settings.
In order to deal with this knowledge gap Ibrahim and coworkers analysed a state-wide (Pennsylvania, USA) database involving 15 116 patients who had a primary diagnosis of PE. Patients with a prior diagnosis of major bleeding were excluded. Specifically, the prevalence of TT together with 30-day and
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
